The global pharmaceutical industry is undergoing a profound transformation, with drug developers increasingly turning to contract development and manufacturing organizations (CDMOs). This shift is especially visible in Europe, where stricter regulatory expectations, pressure on costs, and the rapid rise of complex therapies are pushing both large pharma and biotech companies to rely on specialized partners for advanced dosage forms and highly potent APIs. Within this landscape, Skyepharma, an expert and innovative French CDMO, is emerging as a key player, combining state‑of‑the‑art HPAPI capabilities with cutting‑edge technologies to tackle formulation and manufacturing challenges as well as strict delays and cost effectiveness.
Across the world, pharmaceutical companies are rethinking their operating models and increasingly externalizing development and manufacturing activities to CDMOs. The drivers are multifactorial:
Rapid expansion of biologics and advanced therapies requires sophisticated manufacturing that many pharma companies prefer to outsource to specialized CDMOs.
Oncology is the single largest application segment in the HPAPI CDMO market, that need high‑containment facilities which few pharma companies operate in‑house.
Building or upgrading GMP facilities especially for sterile products, biologics or HPAPIs is extremely capital‑intensive; outsourcing allows companies to convert fixed costs into variable costs and avoid large capital expenditures.
Stricter global regulations, need for continuous process verification, and complex CMC requirements favor experienced CDMOs with established quality systems and multi‑agency inspection histories.
CDMOs help shorten timelines from development to commercial launch by providing ready‑to‑use capacity, experienced tech‑transfer teams, and integrated services, which is critical in crowded and fast‑moving therapeutic areas.
As a result, the global CDMO market has expanded steadily, with many forecasts projecting continued high single‑digit growth over the coming decade, particularly in areas such as biologics, sterile products, and complex small molecules.
Large pharmaceutical companies are divesting non‑core manufacturing assets and focusing their internal resources on discovery, clinical development, and commercialization. By partnering with CDMOs on development and commercial production, they gain flexibility and can quickly scale capacity in response to demand fluctuations, while avoiding the heavy capital expenditures associated with building or upgrading facilities. For smaller biotechs, which often lack any internal manufacturing infrastructure, CDMOs are not just a convenience but an essential enabler for turning promising molecules into marketable medicines.
Beyond capacity, CDMOs also provide deep technical expertise and global regulatory experience, helping sponsors navigate complex CMC (chemistry, manufacturing, and controls) requirements and accelerate time to market. In many therapeutic areas, CDMOs are becoming co‑innovators rather than simple executors, contributing to process optimization, formulation design, and lifecycle management of products.
Here are some numbers :
Highly potent APIs represent another powerful growth engine for CDMOs, especially in fields such as oncology, immunology, and targeted therapies. HPAPIs are often effective at very low doses but pose substantial risks to workers if not handled correctly, requiring sophisticated facility design, strict containment, and robust occupational safety systems.
Because building HPAPI facilities is capital‑intensive and heavily regulated, many pharma companies prefer to partner with CDMOs that already possess the necessary containment technologies and operational experience. Such CDMOs are equipped with negative‑pressure rooms, isolators, advanced air handling and filtration, and specialized cleaning and waste‑management systems. These facilities can safely manage HPAPIs such as OEB4/5+ class across the entire lifecycle, from development and scale‑up to commercial production.
One of the most significant trends shaping the CDMO market is the rapid rise of complex dosage forms. As pipelines shift towards more sophisticated molecules and targeted therapies, traditional immediate‑release tablets and simple injectables are no longer sufficient. Instead, the industry increasingly requires advanced delivery systems to control absorption, improve patient adherence, and differentiate products in competitive markets.
Complex oral solid dosage forms include modified‑release tablets and capsules, multiparticulate systems, fixed‑dose combinations, orally disintegrating tablets, and formulations designed for specific patient populations such as pediatrics or geriatrics. These dosage forms demand specialized formulation know‑how, advanced processing technologies, and robust analytical capabilities. For many companies, developing and industrializing such products in‑house can be prohibitively expensive and time‑consuming.
Within this global and European context, Skyepharma stands out as a specialized CDMO focused on complex oral solid dosage forms and advanced HPAPI capabilities. Based near Lyon, France, Skyepharma operates a GMP facility approved by major regulatory agencies such as the FDA, ANVISA, and the French ANSM, giving it a strong platform to support both European and international clients.
Skyepharma offers end‑to‑end services covering pre‑formulation, analytical development, formulation, scale‑up, clinical and commercial manufacturing, as well as packaging. Its expertise spans immediate‑release and modified‑release oral forms, as well as poor solubility and bioavailability issues.
In line with the rising demand for highly potent therapies, Skyepharma has made significant investments in HPAPI capabilities. We have created facilities capable of managing high‑potency compounds up to demanding containment levels.
These investments include segregated areas with high containment, specialized equipment, and rigorous safety systems designed to protect both operators and products all in GMP & FDA environement. By providing compliant HPAPI handling and processing, we allow our partners to advance oncology and other high‑potency oral therapies without building their own specialized facilities. This is also particularly valuable for smaller companies and biotechs that are developing targeted cancer medicines but lack the capital and expertise to operate HPAPI plants.
Our HPAPI focus connects directly to the broader oncology and specialty‑care boom, positioning Skyepharma as a strategic partner for the development and commercialisation of highly potent oral therapies.
CDMOs are now central to the future of pharmaceutical innovation. Their ability to scale up complex processes, assure quality and regulatory compliance, and deliver sophisticated dosage forms and HPAPI products is directly linked to how quickly and reliably new therapies reach patients worldwide. As cancer, metabolic diseases, inflammatory conditions, and rare diseases become increasingly targeted by complex, potent, and often poorly soluble molecules, the importance of technically advanced CDMOs will only grow.
Skyepharma exemplifies this evolution. By combining expertise in complex oral solid dosage forms, high‑potency manufacturing, and innovative bioavailability‑enhancement technologies, we operate at the crossroads of some of the most important trends in modern drug development.